The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy

Internal Medicine

Volumn 52, Issue 1, 2013, Pages 15-20

  Inoue, Takuya ^a   Murano, Mitsuyuki ^a   Narabayashi, Ken ^a   Okada, Toshihiko ^a   Nouda, Sadaharu ^a   Ishida, Kumi ^a   Kawakami, Ken ^a   Abe, Yosuke ^a   Takeuchi, Toshihisa ^a   Tokioka, Satoshi ^a   Umegaki, Eiji ^a   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Accelerated step up; Tacrolimus; Top down; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MESALAZINE; MICAFUNGIN; SALAZOSULFAPYRIDINE; TACROLIMUS;

ADULT; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPOMAGNESEMIA; MALE; NAUSEA; PANCOLITIS; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; COHORT STUDIES; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PATIENT SAFETY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871983933     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.8555     Document Type: Article

References (33)

1. Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs 65: 2069-2083, 2005.
2. Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 26: 779-794, 2007.
3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121: 255-260, 2001.
4. Flanagan WM, Corthésy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352: 803-807, 1991.
5. Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis. ISRN Gastroenterol 2011: 194324, 2011.
6. Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 46: 129-137, 2011.
7. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841-1845, 1994.
8. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125: 1025-1031, 2003.
9. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 28: 589-597, 2008.
10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629, 1987.
11. Casellas F, Barreiro de Acosta M, Iglesias M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 24: 762-769, 2012.
12. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132: 763-786, 2007.
13. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55: 1255-1262, 2006.
14. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 14: 7-12, 2008.
15. Högenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 18: 415-423, 2003.
16. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10: 1366-1380, 1999.
17. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 8: 317-324, 2002.
18. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 18: 803-808, 2012.
19. Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 17: 22-29, 2011.
20. Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 8: 279-302, 2006.
21. Starzl TE. FK 506 versus cyclosporine. Transplant Proc 25: 511-512, 1993.
22. Yamamoto S, Nakase H, Matsuura M, Masuda S, Inui K, Chiba T. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol 45: 526-530, 2011.
23. López-Palacios N, Mendoza JL, Taxonera C, Lana R, López-Jamar JM, Díaz-Rubio M. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. Eur J Intern Med 22: 621-625, 2011.
24. Sandborn WJ. Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol 3: 16-17, 2007.
25. Cui DJ. Early aggressive therapy for severe extensive ulcerative colitis. World J Gastroenterol 15: 4218-4219, 2009.
26. Cury DB, Cury M.S, Elias GV, Mizsputen SJ. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 15: 1771-1773, 2009.
27. Russo EA, Harris AW, Campbell S, et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 29: 308-314, 2009.
28. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476, 2005.
29. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3: CD005112, 2006.
30. Fascí Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? J Gastrointestin Liver Dis 21: 67-73, 2012.
31. Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol 14: 2670-2677, 2008.
32. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 28: 674-688, 2008.
33. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 140: 1827-1837, 2011.